The Aequitas Group
Health Economic Analysis - Rheumatoid Arthritis
Continuing its efforts to secure appropriate, ongoing reimbursement for its rheumatoid arthritis agent, a global health care company asked The Aequitas Group to review clinical evidence that would directly impact adoption and diffusion in spite of reimbursement changes. This clinical data supported a value analysis demonstrating the cost effectiveness of this agent.
The Aequitas Group developed a model to serve as an algorithm (decision analysis function) for testing assorted sequential therapy strategies, whereby the framework would serve as the backbone of a cost-effectiveness analysis. The analysis was developed from the provider perspective; the cost-effectiveness was developed from a payor perspective.
By developing a decision analytic framework to delineate sequential therapy treatment options for the client’s product and in-class agents The Aequitas Group was able to form a direct comparison of relative strengths and weaknesses of such positioning for each agent as well as develop a model that yielded the cost and cost-effectiveness of such use. This model informed the client’s reimbursement strategy.
© 2009 The Aequitas Group, Inc. All Rights Reserved.